Quisinostat
CAS No. 875320-29-9
Quisinostat ( (JNJ-26481585) )
产品货号. M16360 CAS No. 875320-29-9
Quisinostat (JNJ-26481585) 是一种新型第二代 HDAC 抑制剂,对 HDAC1 具有最高效力,IC50 为 0.11 nM,对 HDAC 2、4、10 和 11 具有中等效力。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥900 | 有现货 |
|
| 10MG | ¥1340 | 有现货 |
|
| 25MG | ¥2186 | 有现货 |
|
| 50MG | ¥3153 | 有现货 |
|
| 100MG | ¥4608 | 有现货 |
|
| 200MG | ¥6462 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥979 | 有现货 |
|
生物学信息
-
产品名称Quisinostat
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Quisinostat (JNJ-26481585) 是一种新型第二代 HDAC 抑制剂,对 HDAC1 具有最高效力,IC50 为 0.11 nM,对 HDAC 2、4、10 和 11 具有中等效力。
-
产品描述Quisinostat (JNJ-26481585) is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM, modest potent to HDACs 2, 4, 10, and 11; greater than 30-fold selectivity against HDACs 3, 5, 8, and 9 and lowest potency to HDACs 6 and 7. Phase 2.(In Vitro):Quisinostat inhibits HDAC isozymes in vitro.Quisinostat (30-1000 nM; 24 hours) is a potent pan-HDAC inhibitor in tumor cells.Quisinostat has a broad spectrum antiproliferative activity against solid and hematologic cancer cell lines and induces apoptosis.(In Vivo):Quisinostat (40 mg/kg; p.o.; once daily; for 3 days) acts as a potent HDAC1 inhibitor p21waf1,cip1 ZsGreen tumors in vivo.Quisinostat induces continuous H3 acetylation in tumor tissue in vivo.Quisinostat (10 mg/kg; once daily; i.p.; for 14 days) strongly inhibits the growth of large pre-established HCT116 colon xenografts.
-
体外实验Quisinostat inhibits HDAC isozymes in vitro.Quisinostat (30-1000 nM; 24 hours) is a potent pan-HDAC inhibitor in tumor cells.?Quisinostat has a broad spectrum antiproliferative activity against solid and hematologic cancer cell lines and induces apoptosis. Western Blot Analysis Cell Line:Human A2780 ovarian carcinoma cellsConcentration:30 nM, 100 nM, 300 nM, 1000 nM Incubation Time:24 hours Result:Induced H3 and H4 acetylation at concentrations as low as 30 to 100 nM.
-
体内实验Quisinostat (40 mg/kg; p.o.; once daily; for 3 days) acts as a potent HDAC1 inhibitor that inhibits p21waf1,cip1 ZsGreen tumors in vivo.Quisinostat induces continuous H3 acetylation in tumor tissue in vivo.Quisinostat (10 mg/kg; once daily; i.p.; for 14 days) strongly inhibits the growth of large pre-established HCT116 colon xenografts. Animal Model:NMRI nude mice, with HCT116 colon carcinoma cells xenografts Dosage:10 mg/kg Administration: Intraperitoneal injection, once daily, for 14 days Result:Strongly inhibited the growth of large pre-established HCT116 colon xenografts.
-
同义词(JNJ-26481585)
-
通路Cell Cycle/DNA Damage
-
靶点HDAC
-
受体HDAC1| HDAC10| HDAC11| HDAC2| HDAC3| HDAC4| HDAC5| HDAC8
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number875320-29-9
-
分子量394.476
-
分子式C21H26N6O2
-
纯度>98% (HPLC)
-
溶解度DMSO:79 mg/mL (200.26 mM); Ethanol:<1 mg/mL (<1 mM); Water:<1 mg/mL (<1 mM)
-
SMILESO=C(C1=CN=C(N2CCC(CNCC3=CN(C)C4=C3C=CC=C4)CC2)N=C1)NO
-
化学全称N-hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Arts J, et al. Clin Cancer Res, 2009, 15(22), 6841-685
产品手册
关联产品
-
Encorafenib
LGX818是一种口服的突变BRaf V600E抑制剂(IC50=0.3 nM),具有潜在的抗肿瘤活性。
-
BRD4097
BRD4097, a negative control in the HDAC1/2/3/8 assay, is a selective histone deacetylase (HDAC3) inhibitor that can be used to protect b-cells and improve insulin resistance, help promote cognitive function and enhance learning and memory formation.
-
Pandacostat
Pandacostat 是第一个非选择性 HDAC 抑制剂 (pan-HDACi)。
021-51111890
购物车()
sales@molnova.cn

